Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6508 in Secondary Hyperparathyroidism in Hemodialysis Patients
NCT06236295Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR6508 in secondary hyperparathyroidism (SHPT), sponsored by Hengrui Therapeutics. Started Feb 2024; status: completed.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT06236295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236295.